# Keros Therapeutics, Inc.: overview KROS · Nasdaq · CIK 1664710 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kros.md) · [Financials](/companies/kros/financials.md) · [Filings](/companies/kros/filings.md) · [Insiders](/companies/kros/insiders.md) Latest reported revenue: [$0](/filings/0001664710-26-000049.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001664710-26-000049). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0001664710-25-000089.md) | [3.0 d](/filings/0001664710-26-000018.md) | [211](/filings/0001664710-26-000030.md) | [18.2](/filings/0001664710-26-000049.md) | [14.3](/filings/0001664710-25-000089.md) | [0.4 d](/filings/0001664710-26-000018.md) | [0.4](/filings/0001664710-26-000030.md) | [0.0](/filings/0001664710-26-000049.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(15117.8%)](/filings/0001664710-25-000089.md) | [(1750.6%) d](/filings/0001664710-26-000018.md) | [72.0%](/filings/0001664710-26-000030.md) | [(219.2%)](/filings/0001664710-26-000049.md) | [(107.9%)](/filings/0001664710-25-000089.md) | [(7602.6%) d](/filings/0001664710-26-000018.md) | [(7051.0%)](/filings/0001664710-26-000030.md) | not reported | | Net margin | % | [(13648.5%)](/filings/0001664710-25-000089.md) | [(1513.0%) d](/filings/0001664710-26-000018.md) | [70.3%](/filings/0001664710-26-000049.md) | [(169.0%)](/filings/0001664710-26-000049.md) | [(51.0%)](/filings/0001664710-25-000089.md) | [(6093.8%) d](/filings/0001664710-26-000018.md) | [(6459.9%)](/filings/0001664710-26-000049.md) | not reported | | Diluted EPS | $ per share | [(1.41)](/filings/0001664710-25-000089.md) | not reported | [3.62](/filings/0001664710-26-000030.md) | [(0.76)](/filings/0001664710-26-000049.md) | [(0.18)](/filings/0001664710-25-000089.md) | not reported | [(1.21)](/filings/0001664710-26-000030.md) | [(1.45)](/filings/0001664710-26-000049.md) | | Free cash flow | $m | [(30.9) d](/filings/0001664710-25-000089.md) | [(46.3) d](/filings/0001664710-26-000018.md) | [161](/filings/0001664710-26-000030.md) | [(30.3) d](/filings/0001664710-26-000049.md) | [3.1 d](/filings/0001664710-25-000089.md) | [(27.4) d](/filings/0001664710-26-000018.md) | [(3.6)](/filings/0001664710-26-000030.md) | [(20.6) d](/filings/0001664710-26-000049.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [20.1](/filings/0001664710-24-000017.md) | [0.0](/filings/0001664710-25-000018.md) | [0.2](/filings/0001664710-25-000018.md) | [3.6](/filings/0001664710-26-000018.md) | [244](/filings/0001664710-26-000018.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(280.5%)](/filings/0001664710-24-000017.md) | not reported | [(112543.7%)](/filings/0001664710-25-000018.md) | [(5939.0%)](/filings/0001664710-26-000018.md) | [27.7%](/filings/0001664710-26-000018.md) | | Net margin | % | [(292.3%)](/filings/0001664710-24-000017.md) | not reported | [(101319.2%)](/filings/0001664710-25-000018.md) | [(5277.5%)](/filings/0001664710-26-000018.md) | [35.7%](/filings/0001664710-26-000018.md) | | Diluted EPS | $ per share | [(2.52)](/filings/0001664710-24-000017.md) | [(4.15)](/filings/0001664710-25-000018.md) | [(5.20)](/filings/0001664710-25-000018.md) | [(5.00)](/filings/0001664710-26-000018.md) | [2.30](/filings/0001664710-26-000018.md) | | Free cash flow | $m | [(63.2)](/filings/0001664710-24-000017.md) | [(71.3)](/filings/0001664710-25-000018.md) | [(127)](/filings/0001664710-25-000018.md) | [(163)](/filings/0001664710-26-000018.md) | [106](/filings/0001664710-26-000018.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kros/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $29.9m | 2,794,217 | | Added +382,424 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $15.1m | 1,410,419 | | Added +50,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $15.1m | 1,410,419 | | Added +50,000 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $10.4m | 967,859 | | Added +561,296 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.9m | 833,596 | | Added +2,175 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $8.1m | 759,155 | | Unchanged | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $7.5m | 700,427 | | Added +11,198 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $7.0m | 652,635 | | Reduced −29,408 | | [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $6.7m | 628,438 | | Added +475,988 | | [Madison Avenue Partners, LP](/funds/1801265.md) | 2026-06-30 | $6.7m | 626,583 | | Unchanged | ## Recent filings [All 528 filings](/companies/kros/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 08:01 ET | [8-K](/filings/0001664710-26-000059.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001664710-26-000059 | | 2026-09-28 | 08:01 ET | [8-K](/filings/0001664710-26-000056.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001664710-26-000056 | | 2026-09-08 | 16:02 ET | [8-K](/filings/0001664710-26-000053.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001664710-26-000053 | | 2026-08-03 | 16:07 ET | [8-K](/filings/0001664710-26-000050.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001664710-26-000050 | | 2026-08-03 | 16:02 ET | [10-Q](/filings/0001664710-26-000049.md) | Quarterly report, period 2026-06-30 | 0001664710-26-000049 | | 2026-08-03 | 16:02 ET | [8-K](/filings/0001664710-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001664710-26-000048 | | 2026-07-30 | 16:01 ET | [8-K](/filings/0001664710-26-000043.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001664710-26-000043 | | 2026-07-22 | 16:01 ET | [8-K](/filings/0001664710-26-000038.md) | 5.02 Departure or appointment of officers or directors | 0001664710-26-000038 | | 2026-06-25 | 16:02 ET | [8-K](/filings/0001664710-26-000036.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001664710-26-000036 | | 2026-06-03 | 16:01 ET | [8-K](/filings/0001664710-26-000034.md) | 5.07 Shareholder vote results | 0001664710-26-000034 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001664710-26-000018.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d608d946-5b66-4249-9fba-80365e0ddd03) ## About the filer - CIK: 1664710 - Tickers: KROS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:11 ET. No prices; not investment advice.